Removing a product from the market, especially one that may have been anticipated to generate significant revenue, can negatively affect a company's financial outlook and investor confidence. The provision of a free drug program for existing patients may also incur costs without generating revenue, further impacting financial performance. However, the ongoing PHOENIX study suggests continued investment in research, which could mitigate some negative perceptions.